Pediatrix Medical Group (NYSE:MD) Price Target Cut to $16.00 by Analysts at Truist Financial

Pediatrix Medical Group (NYSE:MD) had its price target decreased by investment analysts at Truist Financial from $18.00 to $16.00 in a report released on Friday,Benzinga reports. The firm presently has a “hold” rating on the stock. Truist Financial’s price target points to a potential upside of 18.12% from the company’s current price.

Several other equities research analysts have also recently weighed in on MD. StockNews.com upgraded shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research report on Wednesday, January 22nd. UBS Group increased their price target on Pediatrix Medical Group from $16.50 to $18.50 and gave the stock a “neutral” rating in a report on Friday, February 21st. Finally, Macquarie initiated coverage on Pediatrix Medical Group in a research report on Monday, December 16th. They set an “outperform” rating and a $18.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $16.75.

Pediatrix Medical Group Stock Performance

NYSE MD opened at $13.55 on Friday. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -11.29, a PEG ratio of 1.74 and a beta of 1.32. The company has a quick ratio of 1.42, a current ratio of 1.60 and a debt-to-equity ratio of 0.81. Pediatrix Medical Group has a twelve month low of $6.62 and a twelve month high of $17.67. The stock has a fifty day simple moving average of $14.34 and a 200 day simple moving average of $13.89.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings data on Thursday, February 20th. The company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.12. Pediatrix Medical Group had a positive return on equity of 15.47% and a negative net margin of 4.92%. The company had revenue of $502.36 million during the quarter, compared to the consensus estimate of $486.22 million. Sell-side analysts expect that Pediatrix Medical Group will post 1.38 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Pacer Advisors Inc. acquired a new position in shares of Pediatrix Medical Group during the fourth quarter worth approximately $35,492,000. American Century Companies Inc. lifted its stake in shares of Pediatrix Medical Group by 628.2% in the fourth quarter. American Century Companies Inc. now owns 1,739,323 shares of the company’s stock valued at $22,820,000 after buying an additional 1,500,485 shares in the last quarter. Oberweis Asset Management Inc. acquired a new position in shares of Pediatrix Medical Group during the fourth quarter valued at about $6,122,000. Renaissance Technologies LLC increased its position in shares of Pediatrix Medical Group by 117.4% during the fourth quarter. Renaissance Technologies LLC now owns 838,800 shares of the company’s stock worth $11,005,000 after acquiring an additional 453,000 shares in the last quarter. Finally, Boston Partners lifted its position in Pediatrix Medical Group by 25.2% in the 4th quarter. Boston Partners now owns 1,956,353 shares of the company’s stock valued at $25,922,000 after acquiring an additional 393,600 shares in the last quarter. Institutional investors own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.